Juno Therapeutics (JUNO): Price Target and June Short Interest Disclosure

Juno Therapeutics (JUNO) : 9 Wall Street analysts covering Juno Therapeutics (JUNO) believe that the average level the stock could reach for the short term is $52. The maximum price target given is $80 and the minimum target for short term is around $35, hence the standard deviation is calculated at $13.57.

Juno Therapeutics (JUNO), According to the latest information the short interest in Juno Therapeutics, Inc. shot up by 9.5% or 827,981 shares. The final shorts are 13.3% of the total floated shares. The positions increased from 8,719,636 shares on June 15,2016 to 9,547,617 on June 30,2016. According to the per-day average trading of 1,626,215 shares, the days to cover are 6. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 12th.

Also, Barclays initiates coverage on Juno Therapeutics (NASDAQ:JUNO) In a research note issued to the investors, the brokerage major announces price-target of $48 per share.The shares have been rated Equal-weight. The rating by the firm was issued on July 6, 2016.


Juno Therapeutics (NASDAQ:JUNO): On Thursdays trading session , Opening price of the stock was $30.84 with an intraday high of $30.97. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $28.3. However, the stock managed to close at $28.8, a loss of 5.33% for the day. On the previous day, the stock had closed at $30.42. The total traded volume of the day was 7,056,417 shares.

Juno Therapeutics, Inc. (Juno) is a biopharmaceutical company. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Junos product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas. Junos other product candidates include JCAR018: CD22, JCAR023: L1CAM (CD171), JCAR020: MUC-16 / IL-12, ROR-1 and JTCR016: WT-1. JCAR015 is in Phase I open label clinical trial stage for patients with acute lymphoblastic leukemia (r/r ALL). JCAR017 is in Phase I/II trial for patients with pediatric r/r ALL. JCAR014 is in Phase I/II trial as a treatment for various B cell malignancies in patients. JTRC016 is in Phase I/II clinical trial for the treatment of AML, myelodysplasic syndrome and chronic myeloid leukemia.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.